IDiyas

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Michael John Morser

USPTO Granted Patents = 11 

Average Co-Inventor Count = 2.8

ph-index = 8

Forward Citations = 227(Granted Patents)


Company Filing History:

goldMedal7 out of 1,384 
 
Schering Aktiengesellschaft
 patents
silverMedal2 out of 100 
 
Berlex Laboratories, Inc.
 patents
bronzeMedal1 out of 3 
 
Codon
 patents
4. 1 out of 1 
 
Codon Genetic Engineering Laboratories
 patent

Years Active: 1987-2004

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6790828 - Thrombomodulin analogs for pharmaceutical use (2004-09-14),
2. 6632791 - Thrombomodulin analogs for pharmaceutical use (2003-10-14),
3. 6472172 - DNA encoding a novel human inhibitor-of-apoptosis protein (2002-10-29),
4. 5985562 - Method of detecting thrombotic disease risk associated with plasma (1999-11-16),
5. 5864018 - Antibodies to advanced glycosylation end-product receptor polypeptides (1999-01-26),
6. 5702931 - Mutagenesis methods and compositions (1997-12-30),
7. 5466668 - Superior thrombomodulin analogs for pharmaceutical use (1995-11-14),
8. 5256770 - Oxidation resistant thrombomodulin analogs (1993-10-26),
9. 5017478 - Transfected cells containing plasmids having genes oriented in opposing (1991-05-21),
10. 4960702 - Methods for recovery of tissue plasminogen activator (1990-10-02),
11. 4663146 - Methods and compositions for the diagnosis of bloodclots using (1987-05-05),

Certainly! Here is the article about inventor Michael John Morser:

Title: The Innovative Journey of Michael John Morser

Introduction:

Michael John Morser, a prolific inventor based in San Francisco, CA (US), has made significant contributions to the field of pharmaceuticals with his groundbreaking patents. With a total of 11 patents under his name, Morser is recognized for his innovative work in antithrombotic therapy.

Latest Patents:

Morser's latest patents include "Thrombomodulin analogs for pharmaceutical use." These analogs of thrombomodulin are designed to enhance the thrombin-mediated activation of protein C while reducing the activation of thrombin-activatable fibrinolysis inhibitor (TAFI). This innovation holds promise for advancements in antithrombotic therapy.

Career Highlights:

Throughout his career, Michael John Morser has worked with esteemed companies such as Schering Aktiengesellschaft and Berlex Laboratories, Inc. His expertise and dedication to research have led to the development of novel pharmaceutical solutions that address critical medical needs.

Collaborations:

Morser has collaborated closely with talented individuals in the industry, including Mariko Nagashima and David Richard Light. Together, they have pushed the boundaries of innovation in pharmaceuticals, paving the way for new treatment options and advancements in patient care.

Conclusion:

In conclusion, Michael John Morser stands as a trailblazer in the field of pharmaceutical innovation. His patents reflect a deep commitment to improving healthcare outcomes and exploring novel therapeutic strategies. With a proven track record of success, Morser continues to inspire the next generation of inventors in the pursuit of life-changing discoveries in medicine.

Is there anything else you would like to know about Michael John Morser or any other inventor?

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…